| Year |
Citation |
Score |
| 2019 |
Zhu Y, Weldon JE. Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture. Bmc Research Notes. 12: 293. PMID 31133049 DOI: 10.1186/S13104-019-4337-6 |
0.333 |
|
| 2018 |
Hobson JJ, Gallegos AS, Atha BW, Kelly JP, Lein CD, VanOrsdel CE, Weldon JE, Hemm MR. Investigation of amino acid specificity in the CydX small protein shows sequence plasticity at the functional level. Plos One. 13: e0198699. PMID 29912917 DOI: 10.1371/Journal.Pone.0198699 |
0.34 |
|
| 2015 |
Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, Pastan I. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjugate Chemistry. 26: 1120-8. PMID 25997032 DOI: 10.1021/Acs.Bioconjchem.5B00190 |
0.428 |
|
| 2013 |
Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Molecular Cancer Therapeutics. 12: 48-57. PMID 23136186 DOI: 10.1158/1535-7163.Mct-12-0336 |
0.382 |
|
| 2012 |
Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proceedings of the National Academy of Sciences of the United States of America. 109: E3597-603. PMID 23213206 DOI: 10.1073/Pnas.1218138109 |
0.343 |
|
| 2012 |
Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Engineering, Design & Selection : Peds. 25: 1-6. PMID 22101015 DOI: 10.1093/Protein/Gzr053 |
0.428 |
|
| 2011 |
Weldon JE, Pastan I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. The Febs Journal. 278: 4683-700. PMID 21585657 DOI: 10.1111/J.1742-4658.2011.08182.X |
0.325 |
|
| 2011 |
Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Immunotoxins with decreased immunogenicity and improved activity. Leukemia & Lymphoma. 52: 87-90. PMID 21504287 DOI: 10.3109/10428194.2011.573039 |
0.401 |
|
| 2011 |
Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America. 108: 5742-7. PMID 21436054 DOI: 10.1073/Pnas.1102746108 |
0.353 |
|
| 2010 |
Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 297-304. PMID 20445350 DOI: 10.1097/Cji.0B013E3181Cd1164 |
0.417 |
|
| 2009 |
Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood. 113: 3792-800. PMID 18988862 DOI: 10.1182/Blood-2008-08-173195 |
0.382 |
|
| 2008 |
Becerra SP, Perez-Mediavilla LA, Weldon JE, Locatelli-Hoops S, Senanayake P, Notari L, Notario V, Hollyfield JG. Pigment epithelium-derived factor binds to hyaluronan. Mapping of a hyaluronan binding site. The Journal of Biological Chemistry. 283: 33310-20. PMID 18805795 DOI: 10.1074/Jbc.M801287200 |
0.331 |
|
| 2007 |
Weldon JE, Rodgers ME, Larkin C, Schleif RF. Structure and properties of a truely apo form of AraC dimerization domain. Proteins. 66: 646-54. PMID 17173282 DOI: 10.1002/Prot.21267 |
0.522 |
|
| 2006 |
Weldon JE, Schleif RF. Specific interactions by the N-terminal arm inhibit self-association of the AraC dimerization domain. Protein Science : a Publication of the Protein Society. 15: 2828-35. PMID 17132863 DOI: 10.1110/Ps.062327506 |
0.517 |
|
| Show low-probability matches. |